Immunochina Lands $7.5 Million for CAR-T Drug Trials

Beijing 's Immunochina raised $7.5 million to support clinical trials of its CAR-T product for lymphoma. Formed by three graduates PhD graduates from Tsinghua University in 2015, Immunochina has started a Phase II trial of its CAR-T candidate in Acute Lymphocytic Lymphoma patients and a Phase I test in Diffuse Large B-cell Lymphoma. The company expects its CAR-T product will be more effective that US-developed candidates. More details.... Share this with colleagues: // //